GVN adds Sanofi Pasteur as partner against viral threats

By The Science Advisory Board staff writers

March 23, 2021 -- The Global Virus Network (GVN) has added Sanofi Pasteur, the vaccines business unit of Sanofi, as a member of the GVN Healthcare & Pharma Centers of Excellence Coalition, an initiative that brings together pharmaceutical company expertise to lead the war against viruses.

With partners such as Sanofi Pasteur, the GVN is connected to public and private sector entities and is enabled to develop effective and sustainable scientific solutions to address viral threats and viral causes of disease.

International business partners are essential in preparedness against potential pandemics and in stopping the spread of viruses. By collaborating with organizations such as the World Health Organization and the GVN, these businesses can be prepared for and respond to viral disease and epidemics that are becoming far more common.

The GVN enhances the international capacity for reactive, proactive, and interactive activities that address threatening viruses and a global need for coordinated virology training through scholarly exchange programs for recruiting and training young scientists in human and animal virology. The GVN also serves as a resource to governments and international organizations seeking advice about viral disease threats, prevention, or response strategies.

The next generation of COVID-19 vaccines: Gallo on next steps
What will the next generation of COVID-19 vaccines look like? In the first of a two-part series, The Science Advisory Board spoke with pioneering...

Copyright © 2021 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter